Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

September 22, 2023 09:05 ET | Source: AIM ImmunoTech Inc.

AIM ImmunoTech Selected to Present at the 3rd Annual Marie Sklodowska-Curie Symposium on Cancer Research and Care

OCALA, Fla., Sept. 22, 2023 (GLOBE NEWSWIRE) -- AIM ImmunoTech Inc. (NYSE American: AIM) (“AIM” or the “Company”) today announced Chris McAleer, Ph.D., Scientific Officer of AIM will present at the...
September 11, 2023 13:00 ET | Source: AIM ImmunoTech Inc.

AIM ImmunoTech Announces Report of Complete Topline Data from Roswell Park Comprehensive Cancer Center Study Evaluating Ampligen® as a Component of a Chemokine-Modulating (CKM) Regimen, with Paclitaxel, for the Treatment of Early-Stage Triple Negative Breast Cancer

Complete topline results confirm treatment was well tolerated, with promising clinical activity of pathologic complete response (pCR) + microinvasive residual disease (ypTmic) at 66%, comparable to...
September 05, 2023 09:05 ET | Source: AIM ImmunoTech Inc.

AIM ImmunoTech to Present at the H.C. Wainwright 25th Annual Global Investment Conference

OCALA, Fla., Sept. 05, 2023 (GLOBE NEWSWIRE) -- AIM ImmunoTech Inc. (NYSE American: AIM) (“AIM” or the “Company”) today announced that Thomas K. Equels, Chief Executive Officer of AIM, will present...
August 15, 2023 06:45 ET | Source: AIM ImmunoTech Inc.

AIM ImmunoTech Reports Second Quarter Financial Results and Provides Clinical Pipeline Update

– Continued operational execution across pipeline towards multiple clinical and regulatory value-driving milestones expected in the second half of 2023 – Company to host conference call and...
August 09, 2023 09:05 ET | Source: AIM ImmunoTech Inc.

AIM ImmunoTech to Discuss Second Quarter 2023 Financial Results on August 15, 2023, and Host Conference Call and Webcast

OCALA, Fla., Aug. 09, 2023 (GLOBE NEWSWIRE) -- AIM ImmunoTech Inc. (NYSE American: AIM) (“AIM” or the “Company”) announced today that management will host a conference call and webcast to discuss...
August 08, 2023 08:05 ET | Source: AIM ImmunoTech Inc.

AIM ImmunoTech Announces Completion of Enrollment in Phase 2 Study Evaluating Ampligen® for the Treatment of Post-COVID Conditions

OCALA, Fla., Aug. 08, 2023 (GLOBE NEWSWIRE) -- AIM ImmunoTech Inc. (NYSE American: AIM) (“AIM”) today announced the completion of enrollment in the company’s Phase 2 study evaluating Ampligen® as a...
July 18, 2023 19:30 ET | Source: AIM ImmunoTech Inc.

AIM ImmunoTech Issues Notice that an Unaffiliated Third Party and Organization are Providing False Information Related to Relationship with Company and its Affiliates

OCALA, Fla., July 18, 2023 (GLOBE NEWSWIRE) -- AIM ImmunoTech Inc. (NYSE American: AIM) (“AIM” or the “Company”) today issued a notice that the Company has learned that unknown person(s) and/or...
July 10, 2023 12:58 ET | Source: AIM ImmunoTech Inc.

AIMイムノテック (AIM ImmunoTech)、新型コロナウイルス感染症の罹患後症状の治療薬としてAmpligen®を評価する第2相試験で最初の被験者を登録、投薬

アンプリジェンの初期データは、新型コロナウイルス感染症の罹患後症状に対する有効な治療オプションとなる可能性を示す登録完了は2023年第4四半期の予定フロリダ州オカラ発, July 11, 2023 (GLOBE NEWSWIRE) -- AIMイムノテック(NYSE American: AIM) (以下「AIM」)...
July 10, 2023 12:58 ET | Source: AIM ImmunoTech Inc.

AIM ImmunoTech 在评估 Ampligen® 治疗 COVID 后遗症的 2 期研究中招募首位受试者并完成给药

Ampligen 的初步数据显示其有望成为治疗 COVID 后遗症的有效选择预计招募将在 2023 年第四季度完成佛罗里达州奥卡拉, July 11, 2023 (GLOBE NEWSWIRE) -- AIM ImmunoTech Inc. (NYSE American: AIM) (“AIM”)今天宣布已在该公司评估 Ampligen® 作为潜在治疗 COVID 后遗症的药物...
July 10, 2023 08:05 ET | Source: AIM ImmunoTech Inc.

AIM ImmunoTech Enrolls and Doses First Subject in Phase 2 Study Evaluating Ampligen® for the Treatment of Post-COVID Conditions

Preliminary Ampligen data demonstrates potential to be an effective treatment option for post-COVID conditions Enrollment expected to be completed in Q4 2023 OCALA, Fla., July 10, 2023 ...